{"hands_on_practices": [{"introduction": "The primary feature of polycythemia vera is an increased red cell mass, which intuitively suggests a higher capacity for oxygen transport. This exercise [@problem_id:4825681] challenges you to move beyond intuition and quantify this effect precisely. By applying the fundamental equation for arterial oxygen content ($C_{aO2}$), you will calculate how the elevated hemoglobin in a hypothetical patient with polycythemia vera directly impacts the amount of oxygen carried in the blood compared to a healthy individual.", "problem": "A patient with polycythemia vera (PV) has a hemoglobin concentration of $19\\,\\mathrm{g/dL}$. A matched control without PV has a hemoglobin concentration of $15\\,\\mathrm{g/dL}$. Both individuals breathe room air at sea level and have the same arterial oxygen saturation ($S_{aO2}$) of $0.97$ and the same arterial oxygen partial pressure ($P_{aO2}$) of $95\\,\\mathrm{mmHg}$. Use the following widely accepted physiological facts as your fundamental base: (1) each gram of hemoglobin at full saturation can carry $1.34\\,\\mathrm{mL}$ of $\\mathrm{O_2}$, and the amount actually carried is proportional to the fractional saturation; (2) the concentration of dissolved $\\mathrm{O_2}$ in blood is proportional to $P_{aO2}$ with proportionality constant $0.003\\,\\mathrm{mL\\,O_2/dL/mmHg}$. Define arterial oxygen content ($C_{aO2}$) as the sum of hemoglobin-bound $\\mathrm{O_2}$ and physically dissolved $\\mathrm{O_2}$ per $\\mathrm{dL}$ of blood.\n\nStarting from these facts and definitions, construct the expression for $C_{aO2}$ for each individual and compute the ratio of the PV patient’s $C_{aO2}$ to the control’s $C_{aO2}$ under the stated conditions. Report the ratio as a pure number. Round your final answer to four significant figures.", "solution": "The arterial oxygen content, $C_{aO2}$, is defined as the sum of two components: the oxygen bound to hemoglobin ($C_{HbO2}$) and the oxygen physically dissolved in the blood plasma ($C_{dissolved\\,O2}$).\n\n$$C_{aO2} = C_{HbO2} + C_{dissolved\\,O2}$$\n\nThe amount of oxygen bound to hemoglobin, in units of $\\mathrm{mL\\,O_2/dL}$, is the product of the hemoglobin concentration ($Hb$ in $\\mathrm{g/dL}$), the oxygen-carrying capacity of hemoglobin ($k_1$), and the arterial oxygen saturation ($S_{aO2}$).\n\n$$C_{HbO2} = Hb \\times k_1 \\times S_{aO2}$$\n\nThe amount of dissolved oxygen, in units of $\\mathrm{mL\\,O_2/dL}$, is the product of the arterial partial pressure of oxygen ($P_{aO2}$ in $\\mathrm{mmHg}$) and the solubility coefficient of oxygen ($k_2$).\n\n$$C_{dissolved\\,O2} = P_{aO2} \\times k_2$$\n\nCombining these, the general expression for arterial oxygen content is:\n$$C_{aO2} = (Hb \\times k_1 \\times S_{aO2}) + (P_{aO2} \\times k_2)$$\n\nWe will now apply this formula to both the polycythemia vera (PV) patient and the control (C) individual.\n\nFor the PV patient:\n- $Hb_{PV} = 19\\,\\mathrm{g/dL}$\n- $S_{aO2} = 0.97$\n- $P_{aO2} = 95\\,\\mathrm{mmHg}$\n- $k_1 = 1.34\\,\\mathrm{mL/g}$\n- $k_2 = 0.003\\,\\mathrm{mL/dL/mmHg}$\n\nThe arterial oxygen content for the PV patient ($C_{aO2, PV}$) is:\n$$C_{aO2, PV} = (19 \\times 1.34 \\times 0.97) + (95 \\times 0.003)$$\n$$C_{aO2, PV} = (24.6998) + (0.285)$$\n$$C_{aO2, PV} = 24.9848\\,\\mathrm{mL/dL}$$\n\nFor the control individual:\n- $Hb_{C} = 15\\,\\mathrm{g/dL}$\n- $S_{aO2} = 0.97$\n- $P_{aO2} = 95\\,\\mathrm{mmHg}$\n- $k_1 = 1.34\\,\\mathrm{mL/g}$\n- $k_2 = 0.003\\,\\mathrm{mL/dL/mmHg}$\n\nThe arterial oxygen content for the control individual ($C_{aO2, C}$) is:\n$$C_{aO2, C} = (15 \\times 1.34 \\times 0.97) + (95 \\times 0.003)$$\n$$C_{aO2, C} = (19.497) + (0.285)$$\n$$C_{aO2, C} = 19.782\\,\\mathrm{mL/dL}$$\n\nThe problem requires the computation of the ratio of the PV patient’s $C_{aO2}$ to the control’s $C_{aO2}$. Let this ratio be $R$.\n\n$$R = \\frac{C_{aO2, PV}}{C_{aO2, C}}$$\n$$R = \\frac{24.9848}{19.782}$$\n$$R \\approx 1.2630007077...$$\n\nRounding the result to four significant figures as requested:\n$$R \\approx 1.263$$\nThe increased hemoglobin concentration in polycythemia vera leads to a substantially higher arterial oxygen content, despite normal arterial oxygen saturation and partial pressure. This ratio quantifies this increase.", "answer": "$$\\boxed{1.263}$$", "id": "4825681"}, {"introduction": "Diagnosing polycythemia vera is not always straightforward, as other conditions can mimic its presentation or mask its classic signs. A key clinical challenge is \"masked PV,\" where concurrent iron deficiency leads to the production of many small, hemoglobin-poor red cells, keeping the overall hemoglobin and hematocrit deceptively normal. This practice in diagnostic reasoning [@problem_id:4825671] requires you to act as a clinical hematologist, carefully analyzing several patient profiles to distinguish masked PV from other forms of erythrocytosis by integrating clues from the complete blood count, iron studies, and serum erythropoietin levels.", "problem": "A hematology service is asked to adjudicate the cause of erythrocytosis in several patients using red cell indices and iron studies, with the goal of distinguishing a primary myeloproliferative process from a hypoxia- or hormone-driven secondary process when iron is limiting. You are told to focus on the implications of Mean Corpuscular Volume (MCV), Red Cell Distribution Width (RDW), ferritin, and transferrin saturation for the mechanism of erythrocytosis, while integrating how these indices would be expected to behave under primary autonomous erythropoiesis versus secondary erythropoietin-driven erythropoiesis. For each profile below, Red Blood Cell (RBC) count, hemoglobin, hematocrit, and selected ancillary data are also provided to ensure scientific realism.\n\nBased on first principles of iron physiology and myeloproliferative pathophysiology, which profile is most consistent with masked polycythemia vera rather than iron-deficient secondary erythrocytosis?\n\nA. RBC count $7.1 \\times 10^{12}$/L; hemoglobin $15.2$ g/dL; hematocrit $46\\%$; Mean Corpuscular Volume (MCV) $68$ fL; Red Cell Distribution Width (RDW) $18.5\\%$; ferritin $8$ ng/mL; transferrin saturation $6\\%$; platelets $560 \\times 10^{9}$/L; white blood cells $12.5 \\times 10^{9}$/L; Serum Erythropoietin (EPO) $2.8$ mIU/mL; oxygen saturation $98\\%$.\n\nB. RBC count $6.2 \\times 10^{12}$/L; hemoglobin $17.8$ g/dL; hematocrit $54\\%$; MCV $70$ fL; RDW $19\\%$; ferritin $7$ ng/mL; transferrin saturation $5\\%$; platelets $310 \\times 10^{9}$/L; white blood cells $7.8 \\times 10^{9}$/L; EPO $35$ mIU/mL; oxygen saturation $86\\%$ on room air.\n\nC. RBC count $6.5 \\times 10^{12}$/L; hemoglobin $15.0$ g/dL; hematocrit $47\\%$; MCV $64$ fL; RDW $12.5\\%$; ferritin $160$ ng/mL; transferrin saturation $38\\%$; platelets $260 \\times 10^{9}$/L; white blood cells $6.8 \\times 10^{9}$/L; EPO $10$ mIU/mL; oxygen saturation $99\\%$.\n\nD. RBC count $6.8 \\times 10^{12}$/L; hemoglobin $19.1$ g/dL; hematocrit $58\\%$; MCV $88$ fL; RDW $13\\%$; ferritin $120$ ng/mL; transferrin saturation $32\\%$; platelets $720 \\times 10^{9}$/L; white blood cells $14.0 \\times 10^{9}$/L; EPO $2.0$ mIU/mL; oxygen saturation $98\\%$.\n\nSelect the single best answer.", "solution": "The task is to identify the profile most consistent with \"masked polycythemia vera\" (PV) as opposed to \"iron-deficient secondary erythrocytosis.\" This requires a clear understanding of the pathophysiology of these conditions.\n\n**First Principles:**\n\n1.  **Polycythemia Vera (PV)** is a primary myeloproliferative neoplasm (MPN). Its pathophysiology is rooted in a clonal mutation (most commonly *JAK2* V617F) that causes hematopoietic stem cells, particularly erythroid precursors, to proliferate autonomously, independent of the hormone erythropoietin (EPO).\n    -   **Hallmarks of PV**:\n        -   **Autonomous Erythropoiesis**: Production of red blood cells is high regardless of physiological need.\n        -   **Suppressed Serum EPO**: The body's negative feedback system responds to the high red cell mass by shutting down renal EPO production. A low or subnormal serum EPO level is a major diagnostic criterion.\n        -   **Panmyelosis**: The underlying clonal proliferation often affects other cell lines, leading to thrombocytosis (elevated platelet count) and/or leukocytosis (elevated white blood cell count).\n        -   **Iron Depletion**: The massive, ongoing production of red cells consumes large amounts of iron, often leading to iron deficiency (low ferritin, low transferrin saturation).\n\n2.  **Masked Polycythemia Vera**: This is a specific presentation of PV where concurrent iron deficiency is severe enough to impair hemoglobin synthesis. This prevents the hemoglobin (Hgb) and hematocrit (Hct) from reaching the conventionally high levels used for diagnosis (e.g., Hgb > $16.5$ g/dL in men, > $16.0$ g/dL in women per WHO criteria). The \"polycythemia\" is thus \"masked.\"\n    -   **Expected Profile for Masked PV**:\n        -   Hgb/Hct are normal or only mildly elevated, below the usual diagnostic threshold for PV.\n        -   The RBC count is typically high, as the bone marrow produces many small (microcytic) red cells.\n        -   There is clear evidence of iron deficiency: very low ferritin, low transferrin saturation, low MCV, and high RDW (anisocytosis).\n        -   Crucially, the autonomous nature of the disease persists: **serum EPO will be low/suppressed**.\n        -   Evidence of panmyelosis (thrombocytosis and/or leukocytosis) is expected.\n\n3.  **Secondary Erythrocytosis**: This is an appropriate physiological response to a stimulus, typically tissue hypoxia, or a pathological overproduction of EPO from a tumor. It is an EPO-driven process.\n    -   **Hallmarks of Secondary Erythrocytosis**:\n        -   **Elevated Serum EPO**: The high red cell production is driven by high levels of EPO.\n        -   No Panmyelosis: Platelet and WBC counts are typically normal.\n        -   The stimulus is often identifiable (e.g., low blood oxygen saturation in chronic lung disease).\n\n4.  **Iron-Deficient Secondary Erythrocytosis**: This is a scenario where a patient has a reason for secondary erythrocytosis (e.g., hypoxia) and also has concurrent iron deficiency.\n    -   **Expected Profile**:\n        -   Evidence of a stimulus (e.g., low oxygen saturation).\n        -   **Serum EPO will be high**.\n        -   Evidence of iron deficiency (low ferritin, low saturation, low MCV, high RDW).\n        -   Platelet and WBC counts will be normal.\n\nThe key differentiators between masked PV and iron-deficient secondary erythrocytosis are the **serum EPO level** (low in PV, high in secondary) and the **presence of panmyelosis** (present in PV, absent in secondary).\n\n### Option-by-Option Analysis\n\n**A. RBC count $7.1 \\times 10^{12}$/L; hemoglobin $15.2$ g/dL; hematocrit $46\\%$; MCV $68$ fL; RDW $18.5\\%$; ferritin $8$ ng/mL; transferrin saturation $6\\%$; platelets $560 \\times 10^{9}$/L; WBC $12.5 \\times 10^{9}$/L; Serum EPO $2.8$ mIU/mL; oxygen saturation $98\\%$.**\n-   **Erythroid line**: Hgb/Hct ($15.2$ g/dL, $46\\%$) are not elevated to classic PV criteria, consistent with a \"masked\" state. The RBC count is very high ($7.1 \\times 10^{12}$/L).\n-   **Iron status**: Ferritin ($8$ ng/mL) and transferrin saturation ($6\\%$) are very low, indicating profound iron deficiency. This explains the microcytosis (MCV $68$ fL) and anisocytosis (RDW $18.5\\%$).\n-   **Driver**: Serum EPO is low ($2.8$ mIU/mL, reference range typically ~$4$-$26$ mIU/mL), indicating autonomous production, not a secondary response. Normal oxygen saturation ($98\\%$) rules out a hypoxic drive.\n-   **Other lineages**: There is significant thrombocytosis (platelets $560 \\times 10^{9}$/L) and leukocytosis (WBC $12.5 \\times 10^{9}$/L), indicating panmyelosis.\n-   **Conclusion**: This profile perfectly matches the criteria for masked polycythemia vera: masked Hgb/Hct, severe iron deficiency, high RBC count, suppressed EPO, and panmyelosis.\n-   **Verdict**: **Correct**.\n\n**B. RBC count $6.2 \\times 10^{12}$/L; hemoglobin $17.8$ g/dL; hematocrit $54\\%$; MCV $70$ fL; RDW $19\\%$; ferritin $7$ ng/mL; transferrin saturation $5\\%$; platelets $310 \\times 10^{9}$/L; WBC $7.8 \\times 10^{9}$/L; EPO $35$ mIU/mL; oxygen saturation $86\\%$ on room air.**\n-   **Erythroid line**: Hgb/Hct are high ($17.8$ g/dL, $54\\%$), representing overt, not masked, polycythemia.\n-   **Iron status**: The patient is iron deficient (ferritin $7$ ng/mL, sat $5\\%$), explaining the microcytosis (MCV $70$ fL).\n-   **Driver**: Serum EPO is **high** ($35$ mIU/mL). There is a clear stimulus: systemic hypoxia, evidenced by the low oxygen saturation of $86\\%$.\n-   **Other lineages**: Platelet and WBC counts are normal.\n-   **Conclusion**: This is a classic case of secondary erythrocytosis due to hypoxia, with co-existing iron deficiency. It is the antithesis of masked PV.\n-   **Verdict**: **Incorrect**.\n\n**C. RBC count $6.5 \\times 10^{12}$/L; hemoglobin $15.0$ g/dL; hematocrit $47\\%$; MCV $64$ fL; RDW $12.5\\%$; ferritin $160$ ng/mL; transferrin saturation $38\\%$; platelets $260 \\times 10^{9}$/L; WBC $6.8 \\times 10^{9}$/L; EPO $10$ mIU/mL; oxygen saturation $99\\%$.**\n-   **Erythroid line**: Hgb/Hct are normal ($15.0$ g/dL, $47\\%$) with a high RBC count ($6.5 \\times 10^{12}$/L) and marked microcytosis (MCV $64$ fL).\n-   **Iron status**: The patient is iron **replete** (ferritin $160$ ng/mL, sat $38\\%$). Therefore, this cannot be an iron-deficient state. The RDW is normal ($12.5\\%$), which is atypical for iron deficiency but characteristic of uniform microcytosis, such as in thalassemia trait.\n-   **Driver**: EPO is normal ($10$ mIU/mL), neither suppressed nor elevated.\n-   **Other lineages**: Platelet and WBC counts are normal.\n-   **Conclusion**: This profile is inconsistent with either masked PV (no iron deficiency, normal EPO, no panmyelosis) or iron-deficient secondary erythrocytosis. The combination of erythrocytosis, marked microcytosis with a normal RDW, and normal iron studies strongly suggests a hemoglobinopathy like beta-thalassemia minor.\n-   **Verdict**: **Incorrect**.\n\n**D. RBC count $6.8 \\times 10^{12}$/L; hemoglobin $19.1$ g/dL; hematocrit $58\\%$; MCV $88$ fL; RDW $13\\%$; ferritin $120$ ng/mL; transferrin saturation $32\\%$; platelets $720 \\times 10^{9}$/L; WBC $14.0 \\times 10^{9}$/L; EPO $2.0$ mIU/mL; oxygen saturation $98\\%$.**\n-   **Erythroid line**: Hgb/Hct are very high ($19.1$ g/dL, $58\\%$) and MCV is normal ($88$ fL). This is florid, overt polycythemia, not \"masked.\"\n-   **Iron status**: Iron studies are normal (ferritin $120$ ng/mL, sat $32\\%$).\n-   **Driver**: EPO is suppressed ($2.0$ mIU/mL).\n-   **Other lineages**: Marked thrombocytosis (platelets $720 \\times 10^{9}$/L) and leukocytosis (WBC $14.0 \\times 10^{9}$/L) are present.\n-   **Conclusion**: This is a textbook presentation of **classic**, overt polycythemia vera with trilineage myeloproliferation and adequate iron stores. It is not \"masked.\"\n-   **Verdict**: **Incorrect**.\n\nBased on this step-by-step analysis, Profile A is the only one that fulfills all the pathophysiological requirements for masked polycythemia vera.", "answer": "$$\\boxed{A}$$", "id": "4825671"}, {"introduction": "A cornerstone of managing polycythemia vera is therapeutic phlebotomy, a procedure to reduce the patient's red cell mass and lower the risk of thrombotic complications. This problem [@problem_id:4825740] provides a hands-on opportunity to model this vital intervention from first principles. By using the core definitions of hematocrit and volume conservation, you will derive an equation to determine the precise volume of blood that must be removed to reach a target hematocrit, directly connecting pathophysiological parameters to a quantitative treatment plan.", "problem": "A patient with polycythemia vera has increased red blood cell mass and a measured blood volume $BV = 5.0$ L with an initial hematocrit $H_{0} = 0.54$. The clinical team performs isovolemic phlebotomy: each removed volume $v$ of whole blood is replaced $1:1$ with isotonic saline (which contains no red blood cells). Using only the core definitions of hematocrit and conservation of volumes for red blood cells and plasma, derive from first principles an analytic expression for the phlebotomy volume $v$ required to achieve a target hematocrit $H_{t} = 0.45$. Then compute the numerical value of $v$ for the given patient. Round your numerical answer to three significant figures. Express the final volume in liters (L).\n\nFinally, explain qualitatively, using the same definitions and reasoning, how endogenous plasma volume shifts (for example, autotransfusion from the interstitial space) or deviation from $1{:}1$ replacement would alter the computed $v$.", "solution": "The problem requires the derivation of an analytic expression for the phlebotomy volume $v$ needed to reduce a patient's hematocrit from an initial value $H_0$ to a target value $H_t$, given a total blood volume $BV$. The procedure is an isovolemic phlebotomy, where a volume of whole blood is removed and replaced with an equal volume of saline.\n\nThe derivation will be based on the following first principles:\n1.  The definition of hematocrit ($H$) as the ratio of the red blood cell (RBC) volume ($V_{RBC}$) to the total blood volume ($V_{Total}$):\n    $$ H = \\frac{V_{RBC}}{V_{Total}} $$\n2.  The principle of conservation of mass, applied here to the volume of RBCs. The final RBC volume is the initial RBC volume minus the RBC volume removed.\n3.  The condition of isovolemic exchange, meaning the total blood volume remains constant throughout the process.\n\nLet $BV$ be the initial total blood volume, $H_0$ be the initial hematocrit, and $H_t$ be the target hematocrit.\nThe initial volume of red blood cells, $V_{RBC,0}$, is given by:\n$$ V_{RBC,0} = H_0 \\times BV $$\n\nA volume $v$ of whole blood is removed. We model this as a single, discrete event. The blood being removed is assumed to have the composition of the initial bulk blood, i.e., its hematocrit is $H_0$. Therefore, the volume of RBCs removed, $V_{RBC,removed}$, is:\n$$ V_{RBC,removed} = v \\times H_0 $$\n\nThe removed blood volume is replaced by an equal volume of isotonic saline, which contains no red blood cells. Thus, no RBCs are added back into the system. The final volume of RBCs, $V_{RBC,f}$, is the initial volume minus the removed volume:\n$$ V_{RBC,f} = V_{RBC,0} - V_{RBC,removed} $$\nSubstituting the expressions for $V_{RBC,0}$ and $V_{RBC,removed}$:\n$$ V_{RBC,f} = (H_0 \\times BV) - (v \\times H_0) $$\n$$ V_{RBC,f} = H_0 (BV - v) $$\n\nThe procedure is isovolemic, so the final total blood volume, $BV_f$, is equal to the initial blood volume, $BV$.\n$$ BV_f = BV $$\n\nThe target hematocrit, $H_t$, is the ratio of the final RBC volume to the final total blood volume:\n$$ H_t = \\frac{V_{RBC,f}}{BV_f} $$\nSubstituting the expressions for $V_{RBC,f}$ and $BV_f$:\n$$ H_t = \\frac{H_0 (BV - v)}{BV} $$\n\nWe now solve this analytic expression for the required phlebotomy volume, $v$:\n$$ H_t \\times BV = H_0 (BV - v) $$\n$$ H_t \\times BV = H_0 \\times BV - H_0 \\times v $$\n$$ H_0 \\times v = H_0 \\times BV - H_t \\times BV $$\n$$ H_0 \\times v = (H_0 - H_t) BV $$\n$$ v = \\frac{H_0 - H_t}{H_0} BV $$\nThis is the derived analytic expression for the phlebotomy volume $v$.\n\nNext, we compute the numerical value of $v$ using the patient's data:\n-   Initial Blood Volume, $BV = 5.0$ L\n-   Initial Hematocrit, $H_0 = 0.54$\n-   Target Hematocrit, $H_t = 0.45$\n\nSubstituting these values into the derived expression:\n$$ v = \\frac{0.54 - 0.45}{0.54} \\times 5.0 \\, \\text{L} $$\n$$ v = \\frac{0.09}{0.54} \\times 5.0 \\, \\text{L} $$\n$$ v = \\frac{1}{6} \\times 5.0 \\, \\text{L} $$\n$$ v \\approx 0.83333... \\, \\text{L} $$\n\nRounding the result to three significant figures, as requested:\n$$ v \\approx 0.833 \\, \\text{L} $$\n\nFinally, we qualitatively explain how deviations from the ideal model would alter the computed volume $v$. The ideal model assumes a closed system with exact $1:1$ volume replacement.\n\n1.  **Effect of Endogenous Plasma Volume Shifts:**\n    If autotransfusion from the interstitial space occurs, an additional volume of plasma, $V_{shift}$, enters the vascular compartment. This increases the total plasma volume, and thus the total blood volume, without changing the number of RBCs.\n    -   The final RBC volume remains $V_{RBC,f} = H_0(BV - v)$.\n    -   The final total blood volume becomes $BV_f' = BV + V_{shift}$.\n    -   The resulting hematocrit for a given phlebotomy volume $v$ is $H' = \\frac{H_0(BV - v)}{BV + V_{shift}}$.\n    -   Since $BV + V_{shift} > BV$, the plasma influx provides an additional dilution effect. To achieve the same target hematocrit $H_t$, a smaller reduction in RBCs is needed. Therefore, a **smaller** phlebotomy volume $v$ would be required.\n\n2.  **Effect of Deviation from 1:1 Replacement:**\n    a)  **Replacement Volume < Removed Volume:** If the volume of saline infused is less than the volume of blood removed ($v_{rep} < v$), the procedure becomes hypovolemic. The final total blood volume is $BV_f = BV - (v - v_{rep})$, which is less than the initial $BV$. The dilution effect is less pronounced. To achieve the same target hematocrit $H_t$, more RBCs must be removed to compensate for the smaller final plasma volume. Therefore, a **larger** phlebotomy volume $v$ would be required.\n    b)  **Replacement Volume > Removed Volume:** If the volume of saline infused is greater than the volume of blood removed ($v_{rep} > v$), the procedure becomes hypervolemic. The final total blood volume is $BV_f = BV + (v_{rep} - v)$, which is greater than the initial $BV$. This provides an additional dilution effect, similar to the case of autotransfusion. Therefore, to achieve the same target hematocrit $H_t$, a **smaller** phlebotomy volume $v$ would be required.\n\nIn summary, any process that adds plasma volume to the circulation (autotransfusion, hypervolemic replacement) reduces the required phlebotomy volume, while any process that results in a net loss of volume (hypovolemic replacement) increases the required phlebotomy volume.", "answer": "$$\\boxed{0.833}$$", "id": "4825740"}]}